Abstract:Background Aripiprazole (ARI) is often prescribed alone or in combination with other second-generation antipsychotics (SGAs) to treat patients with schizophrenia. However, this may increase the potential clinical significance of drug-drug interactions. Therapeutic drug monitoring (TDM) is an important and fundamental tool both when administering ARI alone and in combination with other SGAs to monitor ARI pharmacokinetics, adjust the dosage and thereby achieve more effective and safer treatment.Aims This study retrospectively investigated the effects of four SGA comedications (clozapine, risperidone, quetiapine (QTP) and olanzapine) and other potential factors (sex, age and ARI dose) on the serum concentrations of ARI and dehydroaripiprazole (DARI) in Chinese patients with schizophrenia using TDM data.Methods High-performance liquid chromatography was used to test the serum concentrations of ARI, DARI and ARI+DARI. In addition, steady-state dose-adjusted serum concentrations (ie, concentration-to-dose ratios, C:D ratios) of ARI, DARI and ARI+DARI; sex; age; ARI dose and SGA comedication dose between 299 inpatients with schizophrenia who received ARI or SGA comedication were all collected and analysed. Spearman's correlation and multiple linear regression analysis were used to evaluate bivariate associations between ARI dose and serum ARI and DARI concentrations and describe the effect of independent variables on serum ARI and DARI concentrations, respectively.Results There were significant differences in the C:D ratios of ARI (chi(2)=-3.21, p=0.001) and ARI+DARI (chi(2)=-2.50, p=0.01) between the ARI and SGA groups, as well as in the C:D ratios of ARI (chi(2)=-3.59, p<0.001) and ARI+DARI (chi(2)=-3.10, p=0.002) between the female patients in the two groups. Of the four SGAs, only QTP had significant effects on the C:D ratios of ARI (Z=-4.12, p<0.001) and ARI+DARI (Z=-3.62, p<0.001) when compared with the ARI group in the whole sample and on the C:D ratios of ARI, DARI and ARI+DARI (Z=-3.96, p<0.001; Z=-2.22, p=0.03; Z=-3.75, p<0.001, respectively) in women when compared with their counterparts in the ARI group.Conclusion Comedication with SGAs resulted in lower C:D ratios of ARI and ARI+DARI compared with ARI monotherapy, and comedication with QTP resulted in lower C:D ratios of ARI and ARI+DARI than ARI monotherapy. Despite this statistical significance of our findings, whether the presently observed effect has clinical significance requires exploration by further research. TDM and dosage regulation of ARI should be performed in Chinese inpatients with schizophrenia who are receiving SGA comedication (especially QTP) to maintain a safe and effective dose-adjusted serum concentration of ARI and DARI.

[Therapeutic drug monitoring of antipsychotic drugs in routine psychiatric practice]

B-303 Stability of Antipsychotic Drugs in Patient Serum and Plasma Clinical Samples

Assessing the Clinical Efficacy of Therapeutic Drug Monitoring for Risperidone and Paliperidone in Patients with Schizophrenia: Insights from a Clinical Data Warehouse

Current Status of Therapeutic Drug Monitoring in Mental Health Treatment: A Review

Therapeutic monitoring of plasma clozapine and N-desmethylclozapine (norclozapine): practical considerations

Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry for Simultaneous Determination of Antipsychotic Drugs in Human Plasma and Its Application in Therapeutic Drug Monitoring

[Therapeutic drug monitoring: A pharmacotherapeutic tool in psychiatry]

Concentration–Effect Relationships of Psychoactive Drugs and the Problem to Calculate Therapeutic Reference Ranges

Microsampling Techniques Suitable for Therapeutic Drug Monitoring of Antipsychotics

Clinical Pharmacokinetics of Atypical Antipsychotics: An Update

Therapeutic Drug Monitoring in Psychiatry: Enhancing Treatment Precision and Patient Outcomes

Effects Of The Combination Of Second-Generation Antipsychotics On Serum Concentrations Of Aripiprazole And Dehydroaripiprazole In Chinese Patients With Schizophrenia

Evidence for Therapeutic Drug Monitoring of Atypical Antipsychotics

Establishing and Extending the Use of Therapeutic Drug Monitoring in Neuropsychopharmacology

Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau"

Adverse Drug Reaction Monitoring in a Tertiary Care Psychiatry Setting: A Comparative Study between Inpatients and Outpatients

The Complexity of Active Metabolites in Therapeutic Drug Monitoring of Psychotropic Drugs

Development of a UPLC-MS/MS method for routine therapeutic drug monitoring of aripiprazole, amisulpride, olanzapine, paliperidone and ziprasidone with a discussion of their therapeutic reference ranges for Chinese patients

Factors influencing concentrations of risperidone and 9-hydroxyrisperidone in psychiatric outpatients taking immediate-release formulations of risperidone

Verification of successful maintenance by serum drug level during a guided antipsychotic reduction to reach minimum effective dose (GARMED) trial

A Simple HPLC-DAD Method for the Therapeutic Monitoring of Clozapine and Related Metabolites in Human Plasma and Urine Samples